Association of Transcranial Alternating Current Stimulation with Digital Cognitive Training for Cognitive Remediation in Older Adults
Launched by UNIVERSIDADE FEDERAL DO RIO DE JANEIRO · Dec 9, 2024
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a combination of two innovative approaches—Digital Cognitive Training (DCT) and Transcranial Alternating Current Stimulation (tACS)—to help improve cognitive function in older adults experiencing cognitive decline. The study aims to see if this combination can be safely used and how well it might work for people with conditions like Mild Cognitive Impairment and Alzheimer's Disease. Participants will take part in five daily sessions that last 30 minutes each, where they will engage in brain training exercises while receiving gentle electrical stimulation to a specific area of the brain that helps with thinking and decision-making.
To be eligible for this trial, participants need to be over 50 years old and experiencing some cognitive complaints, such as memory issues. However, those with certain health conditions, like severe psychiatric or neurological disorders, or those who have had strokes recently, are not eligible. If you or a loved one fits the criteria, this study offers a chance to try out new methods that may help with cognitive function. It’s important to note that the study is currently looking for participants, and all genders are welcome to join.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy subjects over 50 years old, with cognitive complaints
- Exclusion Criteria:
- • Estimated Intelligence Quotient \<80
- • Dependence on psychoactive substances (DSM-V)
- • Severe psychiatric or neurological disorders
- • Uncorrected visual/hearing problems
- • History of syncope for an unexplained reason or seizure less than a year ago
- • Previous stroke
- • Use of anticoagulants
- • Intracranial metallic prosthesis or cardiac pacemaker
- • Any contraindication to performing tACS
About Universidade Federal Do Rio De Janeiro
The Universidade Federal do Rio de Janeiro (UFRJ) is a prestigious higher education institution located in Brazil, renowned for its commitment to academic excellence and research innovation. As a leading sponsor of clinical trials, UFRJ leverages its extensive resources and multidisciplinary expertise to advance medical knowledge and improve patient outcomes. The university fosters collaboration among researchers, healthcare professionals, and industry partners, ensuring rigorous adherence to ethical standards and regulatory compliance. UFRJ is dedicated to contributing to the global scientific community through the development and implementation of cutting-edge clinical research initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rio De Janeiro, Rj, Brazil
Patients applied
Trial Officials
Rogerio Panizzutti, Professor
Principal Investigator
UFRJ
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported